H.C. Wainwright Reiterates Buy Rating on Mirum Pharmaceuticals (MIRM)

June 15, 2026 6:47 AM

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $185.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found